Full access to Entrepreneur for $5
Subscribe

Should Invesco S&P SmallCap 600 Revenue ETF (RWJ) Be on Your Investing Radar?

Style Box ETF report for RWJ

By
This story originally appeared on Zacks

Designed to provide broad exposure to the Small Cap Blend segment of the US equity market, the Invesco S&P SmallCap 600 Revenue ETF (RWJ) is a passively managed exchange traded fund launched on 02/22/2008.

- Zacks

The fund is sponsored by Invesco. It has amassed assets over $627.33 million, making it one of the average sized ETFs attempting to match the Small Cap Blend segment of the US equity market.

Why Small Cap Blend

There's a lot of potential to investing in small cap companies, but with market capitalization below $2 billion, that high potential comes with even higher risk.

Blend ETFs usually hold a mix of growth and value stocks as well as stocks that exhibit both value and growth characteristics.

Costs

Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same.

Annual operating expenses for this ETF are 0.39%, putting it on par with most peer products in the space.

It has a 12-month trailing dividend yield of 0.49%.

Sector Exposure and Top Holdings

While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund's holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation to the Consumer Discretionary sector--about 24.10% of the portfolio. Industrials and Financials round out the top three.

Looking at individual holdings, United Natural Foods Inc (UNFI) accounts for about 3.34% of total assets, followed by Macy's Inc (M) and Core-Mark Holding Co Inc (CORE).

The top 10 holdings account for about 15.99% of total assets under management.

Performance and Risk

RWJ seeks to match the performance of the OFI Revenue Weighted Small Cap Index before fees and expenses. The OFI Revenue Weighted Small Cap Index is constructed by re-weighting the constituent securities of the S&P SmallCap 600 Index according to the revenue earned by the companies in the S&P SmallCap 600 Index.

The ETF has gained about 44.09% so far this year and is up roughly 88.65% in the last one year (as of 09/09/2021). In the past 52-week period, it has traded between $57.89 and $126.04.

The ETF has a beta of 1.49 and standard deviation of 34.45% for the trailing three-year period, making it a high risk choice in the space. With about 602 holdings, it effectively diversifies company-specific risk.

Alternatives

Invesco S&P SmallCap 600 Revenue ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, RWJ is a sufficient option for those seeking exposure to the Style Box - Small Cap Blend area of the market. Investors might also want to consider some other ETF options in the space.

The iShares Russell 2000 ETF (IWM) and the iShares Core S&P SmallCap ETF (IJR) track a similar index. While iShares Russell 2000 ETF has $67.43 billion in assets, iShares Core S&P SmallCap ETF has $68.97 billion. IWM has an expense ratio of 0.19% and IJR charges 0.06%.

Bottom-Line

An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transparency, flexibility, and tax efficiency; they are also excellent vehicles for long term investors.

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.



Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Invesco S&P SmallCap 600 Revenue ETF (RWJ): ETF Research Reports

 

Macys, Inc. (M): Free Stock Analysis Report

 

United Natural Foods, Inc. (UNFI): Free Stock Analysis Report

 

iShares Russell 2000 ETF (IWM): ETF Research Reports

 

iShares Core S&P SmallCap ETF (IJR): ETF Research Reports

 

To read this article on Zacks.com click here.